Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.

Erin E CrottySarah E S LearyJ Russell GeyerJames M OlsonNathan E MillardAimee A SatoRalph P ErmoianBonnie L ColeChristina M LockwoodVera A PaulsonSamuel R BrowdRichard G EllenbogenJason S HauptmanAmy LeeJeffrey G OjemannNicholas A Vitanza

Published in: Journal of neuro-oncology (2020)

Our single-center experience demonstrates tolerability of this 3-drug regimen, with prolonged survival in DIPG compared to historical single-agent temozolomide. pHGG survival was comparable to analogous 3-drug regimens and superior to historical agents; however, cure was rare. Children with pHGG remain excellent candidates for the study of novel therapeutics combined with standard therapy.

Keyphrases

young adults
high grade
healthcare
emergency department
small molecule
adverse drug
randomized controlled trial
stem cells
open label
bone marrow
mesenchymal stem cells
replacement therapy